107 related articles for article (PubMed ID: 27864603)
1. Presence of risk factors does not affect outcome in early stage pediatric Hodgkin lymphoma treated with ABVD.
Bhethanabhotla S; Bakhshi S
Ann Hematol; 2017 Mar; 96(3):521-522. PubMed ID: 27864603
[No Abstract] [Full Text] [Related]
2. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
[TBL] [Abstract][Full Text] [Related]
3. Acquired Glanzmann thrombasthenia associated with Hodgkin lymphoma: rapid reversal of functional platelet defect with ABVD (adriamycin/bleomycin/vinblastine/dacarbazine) chemotherapy.
Raman V; Quillen K; Sloan JM
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):e51-4. PubMed ID: 24342105
[No Abstract] [Full Text] [Related]
4. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
[TBL] [Abstract][Full Text] [Related]
5. Hodgkin's disease in HIV-infected patients: report of eight cases usefully treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus granulocyte colony- stimulating factor.
Gastaldi R; Martino P; Gentile G; Picardi V; De Propris MS; Pirillo MF; De Vellis A; Mandelli F
Ann Oncol; 2002 Jul; 13(7):1158-60. PubMed ID: 12176798
[No Abstract] [Full Text] [Related]
6. [Hodgkin lymphoma--ABVD regimen].
Nagai H
Nihon Rinsho; 2015 Feb; 73 Suppl 2():642-5. PubMed ID: 25831839
[No Abstract] [Full Text] [Related]
7. Hodgkin lymphoma among patients infected with HIV in post-HAART era.
Tanaka PY; Pessoa VP; Pracchia LF; Buccheri V; Chamone DA; Calore EE
Clin Lymphoma Myeloma; 2007 Mar; 7(5):364-8. PubMed ID: 17562247
[TBL] [Abstract][Full Text] [Related]
8. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?
Laskar S; Gupta T; Vimal S; Muckaden MA; Saikia TK; Pai SK; Naresh KN; Dinshaw KA
J Clin Oncol; 2004 Jan; 22(1):62-8. PubMed ID: 14657226
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and efficacy of dose-dense and dose-intense ABVD for high-risk patients with advanced Hodgkin lymphoma: reply to D'Arco et al.
Pinto A; Corazzelli G
Br J Haematol; 2015 Nov; 171(4):665-8. PubMed ID: 25892204
[No Abstract] [Full Text] [Related]
10. Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
Iannitto E; Minardi V; Gobbi PG; Calvaruso G; Tripodo C; Marcheselli L; Luminari S; Merli F; Baldini L; Stelitano C; Callea V; Petrini M; Angrilli F; Quarta G; Vallisa D; Molica S; Liardo E; Polimeno G; Brugiatelli M; Federico M
Clin Lymphoma Myeloma; 2009 Apr; 9(2):138-44. PubMed ID: 19406724
[TBL] [Abstract][Full Text] [Related]
11. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
Chisesi T; Bellei M; Luminari S; Montanini A; Marcheselli L; Levis A; Gobbi P; Vitolo U; Stelitano C; Pavone V; Merli F; Liberati M; Baldini L; Bordonaro R; Pesce EA; Federico M
J Clin Oncol; 2011 Nov; 29(32):4227-33. PubMed ID: 21990405
[TBL] [Abstract][Full Text] [Related]
13. [ABVD chemotherapy for Hodgkin lymphoma at a single institute].
Ohshima R; Motomura S; Hashimoto C; Miyazaki T; Ito S; Takasaki H; Hyo R; Koharazawa H; Takemura S; Yamazaki E; Fujimaki K; Tomita N; Fujita H; Fujisawa S; Harano H; Kanamori H; Ishigatsubo Y
Rinsho Ketsueki; 2010 Dec; 51(12):1756-61. PubMed ID: 21258185
[TBL] [Abstract][Full Text] [Related]
14. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS
Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131
[TBL] [Abstract][Full Text] [Related]
15. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
Pavlovsky S; Corrado C; Pavlovsky MA; Prates MV; Zoppegno L; Giunta M; Cerutti I; Palomino E; Pagani F; Lastiri F; Bar D; Bezares RF; Avila G
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):181-5. PubMed ID: 20511162
[TBL] [Abstract][Full Text] [Related]
16. [Effectiveness and toxicity of MOPP, ABVD, BEACOPP chemotherapy in first-diagnosed Hodgkin lymphoma with a poor prognosis].
Filatova LV; Plotnikova AA; Gershanovich ML; Semiglazova TIu
Vopr Onkol; 2013; 59(2):59-65. PubMed ID: 23814851
[TBL] [Abstract][Full Text] [Related]
17. Unusual manifestation of Hodgkin disease.
Dunlap N; Parkhie S
Am J Clin Oncol; 2006 Oct; 29(5):529-30. PubMed ID: 17023792
[No Abstract] [Full Text] [Related]
18. Prognostic Significance of IL-6 in Hodgkin Lymphoma.
Bhethanabhotla S; Tiwari A; Sharma MC; Vishnubhatla S; Bakhshi S
Indian J Pediatr; 2019 Jun; 86(6):551-554. PubMed ID: 30830568
[TBL] [Abstract][Full Text] [Related]
19. ABVD associated with imatinib for coexisting chronic myeloid leukaemia and relapsed Hodgkin lymphoma.
Ferrario A; Radaelli F; Goldaniga M; F FG; Olivero B; Rossi F; Baldini L
Leuk Res; 2010 Oct; 34(10):e280-1. PubMed ID: 20605208
[No Abstract] [Full Text] [Related]
20. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]